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Abstract 
Objective: To assess Illinois pharmacists’ (1) baseline knowledge of CBD and self-rated competency of OTC-CBD product 
pharmacotherapy, (2) concerns about OTC-CBD product safety and level of preparedness with answering questions about the product, 
and (3) current and future interest in learning more about these types of products to target an area of need for continuing education 
in the pharmacy field.  
Design: This observational cross-sectional study used a quantitative survey to obtain information about Illinois pharmacists’ 
knowledge, concerns and educational needs about OTC-CBD products. Survey questions were based on prior research and pilot tested 
for clarity and completeness. Descriptive statistics were utilized to assess all data. 
Setting and Participants: The study researchers collaborated with two state-based pharmacy organizations to distribute the survey 
online with up to two reminders. 
Results: A total of 181 participants completed the survey. Majority of the respondents were 31-60 years of age, had worked in 
pharmacy for less than 5 years, in a geographic location with a population of 50,000 or more. About 41% worked in hospital-based 
practice setting and 39.2% work in a community-based setting. Most pharmacists (64.1%) reported ever being asked about the safety 
or efficacy of cannabidiol containing products, and only 20.7% responded that they felt moderately/highly prepared to provide 
medication counseling to patients who use OTC-CBD products. Majority of respondents reported being concerned about safety, quality, 
and regulations related to OTC-CBD products. Almost all respondents indicated that information about state (90.5%) and federal 
(89.4%) laws related to CBD, and safety (99.5%) were preferred topics for future education. 
Conclusions: Consumers are seeking information about CBD containing products; however, many pharmacists do not feel prepared 
when it comes to being the drug expert for these products. Educational opportunities are necessary for pharmacists to become more 
comfortable and knowledgeable regarding safe and effective use of CBD-OTC containing products.  
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Background 
Cannabidiol (CBD) is a chemical compound found in cannabis.1 
CBD has little effect on the intracranial self-stimulation pathway 
with cannabinoid1 (CB) receptors, unlike another component of 
cannabis, tetrahydrocannabinol (THC). CBD derived from a 
hemp plant, containing less than 0.3% THC, is deemed as a 
relatively safe agent that does not produce the “high” feeling 
associated with marijuana. Limited evidence from well-
controlled human experimental research shows that the lower 
concentration of hemp-derived CBD lacks abusive potential.1,2,3 
These low concentration, hemp-derived CBD products are 
available over-the- counter (OTC) in a wide variety of 
formulations, such as capsules, oil solution, sublingual units, 
intranasal sprays, and topical preparations.1,4  
 
Recently there has been an increased public interest in the use 
of CBD for a variety of ailments. Early in 2018, then Illinois 
Governor, Bruce Rauner, signed the Illinois Industrial Hemp 
Pilot Program into law to allow cultivation of hemp in Illinois.10 
Later the same year, Congress signed the 2018 Farm Bill, 
federally legalizing cultivation of hemp nationwide. The bill  
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states that hemp-cultivated CBD must have less than 0.3% THC 
contained in the product.11  
 
In 2016, CBD sales in the US were $170 million. It is now 
estimated that sales will continue to trend upwards to over $1 
billion by 2021.12 Over the counter (OTC) CBD-containing 
products are not approved by the Food and Drug 
Administration (FDA). Therefore, there is no strict regulation on 
the manufacturing of these products. The lack of FDA approval 
means that OTC-CBD products cannot be sold as “therapeutic” 
medication (i.e., drug).13 Currently, Epidiolex (manufactured by 
Greenwich Biosciences) is the only FDA approved prescription 
CBD-containing product and is dispensed as an oral solution.14  
 
Given the widespread availability of OTC-CBD products in 
pharmacies, pharmacists play an important role in 
understanding and communicating the impact of using OTC-
CBD products. Marijuana is still classified as a Schedule I 
controlled substance in many states, and pharmacy schools 
incorporate limited discussion of various cannabis products 
within their curricula.15 This is affecting pharmacy students, as 
well as practicing pharmacists, who have sparse continuing 
education opportunities for OTC-CBD products. A study of 
Minnesota registered pharmacists assessed the baseline 
medical marijuana knowledge, concerns, and preparedness to 
dispense the products before the state’s medical marijuana 
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program took effect.16 Results of the study showed that 
pharmacists were not aware of the state-level laws and 
regulations regarding medical marijuana. Many of them also 
noted not having enough education on the pharmacokinetics 
and pharmacodynamics of the products to provide efficient 
counseling to patients. Further, a small study (n=34) of 
Australian pharmacists highlighted concern for federal 
legalization of medical cannabis, including quality of products, 
long-term safety and abuse profiles, and stigma associated with 
use.17  
 
While these few studies assess the pharmacists’ stance on their 
own capability to manage patients’ use of medical marijuana, 
none have specifically studied OTC-CBD products. Therefore, 
this study serves the purpose of assessing pharmacists’ 
awareness of the OTC-CBD products. 
 
Objectives 
The objectives of this study are to assess pharmacists’  
(1) baseline knowledge of CBD and self-rated competency of 
OTC-CBD product pharmacotherapy, (2) concerns about OTC-
CBD product safety and level of preparedness with answering 
questions about the product, and (3) current and future interest 
in learning more about these types of products to target an area 
of need for continuing education in the pharmacy field.  
 
Methods 
Study Design 
This observational cross-sectional study used a quantitative 
survey to collect information about pharmacists’ knowledge of 
OTC-CBD products, their level of preparedness to counsel the 
patients on OTC-CBD products, as well as their interest in 
learning more about these products. An email containing a link 
to the questionnaire was sent to all pharmacists who were 
members of Illinois Pharmacists Association (IPhA) and/or 
Illinois Council of Health-System Pharmacists (ICHP). Within the 
email, information was provided to the participants about study 
objectives and survey anonymity. It was also explained that the 
survey is voluntary, and only pharmacists holding an active 
Illinois pharmacy practice license should participate. Only those 
consenting to the study had access to the survey. Data was 
collected through an online survey platform, Qualtrics, from 
August 15th, 2019 to September 30th, 2019 with one reminder 
sent by ICHP (approximately 2 weeks later) and two reminders 
sent by IPhA (approximately 2 weeks apart).  
 
Survey 
 A 20-question survey was assessed for face validity by two 
Southern Illinois University Edwardsville faculty pharmacists. 
The survey items were based on previous medical marijuana 
literature, and were modified to suit the current survey needs.16 
The initial draft was modified based on faculty feedback and 
then piloted among four practicing pharmacists. The wording of 
questions and available responses were revised to improve the 
flow and readability of the survey. The final survey assessed the 
pharmacists’ demographic information (i.e. age, number of 
years working as a pharmacist, practice site, setting), objective 
1: knowledge about cannabidiol  and OTC-CBD products and 
laws (6 questions given as true/false or multiple choice), self- 
assessed competency in pharmacotherapy of OTC-CBD 
products (3 questions on Likert-type scales), objective 2: 
concerns about safety of OTC-CBD products (5 questions on 
Likert-type scale), and level of preparedness for counseling 
patients and discussing with health care providers (2 questions 
on Likert-type scales), and objective 3: current and future 
educational needs (4 questions assessing preference). The final 
draft of the survey, informed consent form, and methodology 
were approved by the Institutional Review Board of Southern 
Illinois University at Edwardsville.  
 
Study Sample 
Current members of IPhA and/or ICHP who had an active Illinois 
pharmacy practice license and consented to participate in the 
survey were included in the study. The survey was electronically 
delivered to 4,368 IPhA members and 538 ICHP members with 
a total of 181 members responding to the survey. Since an 
overlap of membership between the two organizations is likely, 
an accurate denominator, and therefore response rate, could 
not be calculated. 
 
Statistical Analysis 
Results were summarized with descriptive analysis using 
Microsoft Excel. Objective 1: knowledge about cannabidiol and 
OTC-CBD products and laws was assessed as correct/incorrect 
based on the responses provided, self- assessed competency in 
pharmacotherapy of OTC-CBD products was assessed using 
Likert-type scale (strongly competent – strongly incompetent). 
Objective 2: concerns about safety of OTC-CBD products were 
assessed using Likert-type scale (no concern – highly 
concerned), level of preparedness for counseling patients and 
discussing with health care providers were assessed also using 
Likert-type scale (not at all prepared – highly prepared). 
Objective 3: current and future interest in CBD related 
education was assessed using a preference scale. Likert-type 
responses were assessed by combining sparse categories (e.g. 
no concern, slight/somewhat concern, and moderate/high 
concern).  
 
Results 
Demographics 
A total of 181 pharmacists participated in the survey. Table 1 
describes the sample demographics and practice-related 
experiences of the sample. A majority of the participants were 
between the ages of 31-60 years old, had worked in pharmacy 
for less than 5 years, in a geographic location with a population 
of 50,000 or more. The two most prominent pharmacy 
workplace settings were hospital (40.9%) and community 
(independent-22.1%; chain-17.1%). When asked if a patient has 
ever inquired about the safety or efficacy of OTC-CBD products, 
116 pharmacists (64.1%) reported yes, with 89.6% of those 
participants reported having at least one encounter within the 
previous month.   
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Objective 1: Knowledge assessment and Self-rated competency 
of OTC-CBD product pharmacotherapy 
 
Six content-based questions were asked to the participants that 
covered OTC-CBD product properties, indications, dosage 
forms, and laws and regulations (Table 2 and Figures 1 & 2). In 
general, participant knowledge about OTC-CBD products was 
lacking, however, a majority identified that OTC-CBD is not 
approved by the FDA (Table 2). Incidentally, since the 
dissemination of this survey, Elixicure, a CBD-infused pain relief 
product, has been certified by the FDA. This certification is not 
an indication of the FDA’s approval, but allows for the product 
to be included in the national drug code directory.18 Participant 
knowledge about OTC-CBD scheduling and type of dosage 
forms was also found to be limited (Figures 1 & 2). Lastly, a total 
of 63% of participants rated themselves as incompetent 
regarding knowledge of pharmacokinetics and 
pharmacodynamics of OTC-CBD products (Table 3). 
 
Objective 2: Concerns about OTC-CBD product safety and level 
of preparedness with answering questions about the product 
 
A majority of participants reported being moderately/highly 
concerned about the consistency in quality of OTC-CBD 
products (87.2%) and the safety of OTC-CBD products (69.4%). 
Pharmacists also reported feeling unprepared to discuss OTC-
CBD products with other health care providers as well as to 
counsel patients about these products (Table 4).  
 
Objective 3: Current and future continuing education 
 
Current continuing education was defined as any continuing 
education credit received within the past two years. A number 
of pharmacists sought continuing education related to CBD in 
the past two years (42%). Participants also reported seeking 
CBD-related information independently from internet searches 
(33.3%), followed by the IPhA (18.6%). A few participants also 
reported “other” as a source of information, noting PubMed, 
employer-provided information, and local/state conferences as 
sources of information for cannabidiol. (Table 5). OTC-CBD 
product safety and pharmacotherapy were the most preferred 
education topics among participants. Online courses and emails 
were the most preferred method to receive CBD-related 
information (Figure 3). 
 
Discussion 
Hemp-derived CBD products containing less than 0.3% THC are 
OTC products that have recently surged in popularity. While 
most previous research focuses on medical marijuana that 
contains 0.4% or more THC and requires a prescription, this 
study focused on the OTC-CBD products which are more likely 
to be encountered on the shelves of pharmacies.16 Since Illinois 
legalized hemp-derived CBD in 2018, this study is an early 
assessment of Illinois pharmacists’ knowledge and comfort with 
OTC-CBD products. The findings of this study indicated a lack of 
knowledge about these products, significant concerns about 
the safety and quality of these products, lack of preparedness 
in discussing these products with patients and health care 
providers and a need for continuing education about CBD 
products among Illinois pharmacists. This study provides a 
baseline understanding of Illinois pharmacist OTC-CBD 
knowledge. A common misconception exists among the general 
public regarding the potential for euphoric effects from OTC-
CBD use. OTC-CBD products do not contain a significant amount 
of THC, reducing the likelihood of causing a euphoric effect in 
users, and are generally considered safe by the World Health 
Organization (WHO).1 Although 55% of respondent pharmacists 
correctly identified this fact, there were still many unaware that 
OTC-CBD products contain less than 0.3% THC do not produce 
a euphoric effect. Additionally, a majority of participants 
consider OTC-CBD products to be unsafe for use by the general 
public.  Safety and efficacy of these products remains under 
investigation and there is a lot that is unknown.19 OTC-CBD 
products with less than 0.3% THC have a low dependency 
potential and a wide therapeutic index.20 Common adverse 
effects reported include somnolence, fatigue, diarrhea, and 
lack of appetite.20 As this research develops, pharmacists would 
benefit from targeted OTC-CBD product safety and efficacy 
information. Another concern is the lack of knowledge of 
dosage form availability for OTC-CBD products. Although 
participants identified only one FDA approved dosage form 
(Epidiolex solution), about 80% of respondents were unable to 
identify all OTC-CBD dosage forms on the market. This is 
problematic when obtaining a medication history from a 
patient due to not reiterating all forms of medication that may 
be available for patient purchase OTC.   
 
Many pharmacists report feeling incompetent discussing 
pharmacokinetics and pharmacodynamics of OTC-CBD 
products with patients and other health care professionals. 
Many also identified concerns about quality, consistency, 
efficacy, and safety of OTC-CBD products. Being a medication 
expert, counseling patients and talking with other health care 
providers about medications is a primary role of pharmacists. 
Not understanding the entire product may leave patients and 
providers at a disadvantage. Without having the proper 
knowledge of how these products work, a patient’s health may 
be impacted in the form of adverse events or drug interactions. 
In general, CBD and THC are known to inhibit cytochrome P450 
2C9, an enzyme used in the metabolism of several 
medications.20 For instance, case studies have provided 
evidence of an increased risk of bleeding when CBD is combined 
with warfarin.21 Comprehensive, large scale studies, however, 
are lacking which makes it difficult to ascertain clinical 
significance of the available literature.  
 
A substantial number of participants (42%) reported attending 
CBD-focused continuing education sessions within the past two 
years. Participants also sought out CBD-focused education 
independently through internet searches, PubMed, and 
pharmacy organizations. Additionally, respondents stated that 
they were interested in receiving further education on CBD, 
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specifically pharmacotherapy and safety topics. This clearly 
indicates the growing demand for CBD product-focused 
continuing education. While continuing education is being 
provided at national conferences, it may not be enough to 
accommodate all pharmacists.22 In order to bridge the 
knowledge gap, continuing education needs to be accessible 
through a widely available platform, such as an online course. 
 
A strength of this study is the utilization of two large pharmacy 
organizations from the state of Illinois, which captures a wide 
variety of pharmacists throughout the state. Additionally, the 
study sample had pharmacists with a variety of ages, practice 
sites and level of experience that participated in the survey.  
 
Limitations of this study include small sample size and response 
rate. Due to the survey going out to two Illinois pharmacist 
organizations, it is possible that some participants may be a 
member of both organizations, making it difficult to calculate 
the true denominator and thus an accurate response rate. 
Although this survey reached a wide range of participants from 
different practice sites with varying levels of experience, the 
small sample size means we cannot eliminate non-response 
bias. Additionally, pharmacists who are not members of either 
organization were not surveyed in this study. Lastly, the 
researchers noted that one knowledge-based question about 
the most studied indication of OTC-CBD had the correct answer 
blocked from selection by participants in the online portal. Due 
to this error, the question was not included in the analysis. In 
addition, this analysis did not link knowledge to the concerns 
expressed with OTC-CBD. 
 
Conclusion 
The results of this study suggest that Illinois pharmacists are in 
need of additional education to be able to adequately assist 
consumers and health care professionals on OTC-CBD products. 
A majority of Illinois pharmacists are concerned about the 
safety and efficacy, and feel unprepared to speak to consumers 
and other health care providers about OTC-CBD products. 
Therefore, continuing education targeting federal and state 
CBD regulations, pharmacotherapy and safety, and available 
product dosage forms should be made available for 
pharmacists and other health care professionals practicing in 
Illinois. 
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Table 1: Sample demographics and characteristics 
 
  
Sample Demographics and Characteristics N=181 
N (%) 
What is your age range (in years)?  
 22-30 34 (18.8) 
 31-40 57 (31.5) 
 41-50 30 (16.6) 
 51-60 22 (12.2) 
 61-70 30 (16.6) 
 70+ 8 (4.4) 
How many years have you worked as a pharmacist?  
 Less than 5 39 (21.5) 
 5-10 31 (17.1) 
 11-20 40 (22.1) 
 21-30 25 (13.8) 
 31-40 21 (11.6) 
 40+ 25 (13.8) 
Which of the following areas do you practice in?  
 Area with a population of less than 50,0000 49 (27.4) 
 Area with a population of 50,000 or more 102 (57) 
 Both  28 (15.6) 
What is your primary pharmacy practice setting?^  
 Academia 32 (17.7) 
 Community-Independent 40 (22.1) 
 Community-Chain 31 (17.1) 
 Clinic 18 (9.9) 
 Managed Care 3 (1.7) 
 Hospital 74 (40.9) 
 Hospice/Assisted Living 1 (0.6) 
 Industry 3 (1.7) 
 Other 13 (7.2) 
Has a patient ever asked you about the safety or efficacy of cannabidiol (CBD) containing products?  
 Yes 116 (64.1) 
 No 65 (35.9) 
If yes, how many times in the past month have you been asked by a patient about cannabidiol (CBD) 
containing products? 
 
 Zero 12 (10.3) 
 1-2 times 53 (45.7) 
 3- 4 times 18 (15.5) 
 5+ times 33 (28.4) 
^ Participants were able to select more than one response on this question.  
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Table 2: Knowledge assessment about OTC-CBD products 
 Answered 
Correctly 
N (%) 
Answered 
Incorrectly 
N (%) 
Unsure 
N (%) 
It is likely for over the counter cannabidiol (CBD) products that 
contain no more than 0.3% tetrahydrocannabinols (THC) to exert 
euphoric effects on the user. 
 
99 (55.0) 
 
26 (14.4) 
 
55 (30.6) 
Over the counter cannabidiol (CBD) containing products (i.e. oils, 
topical products, capsules) are FDA-approved products. 
 
163 (90.1) 
 
6 (3.3) 
 
12 (6.6) 
According to the World Health Organization’s Expert Committee on 
Drug Dependence, cannabidiol (CBD) is generally well tolerated in 
humans with a good safety profile. 
 
79 (43.6) 
 
18 (9.9) 
 
84 (46.4) 
Under the Federal Controlled Substances Act, cannabis derived 
cannabidiol (CBD) prescription drugs that contain no more than 0.3% 
tetrahydrocannabinols (THC) are classified under what drug 
schedule?# 
 
55 (30.1) 
 
126 (69.9%) 
 
N/A 
Which of the following are ways in which over the counter 
cannabidiol (CBD) is used?# 
 
43 (23.8) 
 
138 (76.2) 
 
N/A 
# More specific responses are available in Figures 1 and 2 
 
 
 
Table 3: Self-reported Competency Assessments in pharmacotherapy knowledge of OTC-CBD Products 
Rate your competency level in over the counter cannabidiol (CBD) products pharmacotherapy 
knowledge in the following areas 
Competent 
N (%) 
Incompetent 
N (%) 
Pharmacology 85 (47.2) 95 (52.8) 
Pharmacokinetics 65 (36.5) 113 (63.5) 
Pharmacodynamics 66 (36.9) 113 (63.1) 
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Table 4: Concerns and level of preparedness about OTC-CBD products 
Concerns No Concern 
N (%) 
Slightly/ Somewhat 
Concerned 
N (%) 
Moderately/ Highly 
Concerned 
N (%) 
Safety of OTC CBD products use (ex: drug 
interactions, contraindications, and adverse 
reactions) 
 
5 (2.8) 
 
61 (33.7) 
 
115 (63.5) 
Consistency in quality of OTC CBD products  
3 (1.7) 
 
20 (11.1) 
 
157 (87.2) 
Federal regulation related to OTC CBD 
products 
 
7 (3.9) 
 
49 (27.2) 
 
124 (68.9) 
Psychoactive effect and potential addiction 
from OTC CBD products  
 
42 (23.5) 
 
73 (40.8) 
 
64 (35.8) 
Limited evidence of therapeutic benefits from 
OTC CBD products  
 
14 (7.8) 
 
41 (22.8) 
 
125 (69.4) 
Level of Preparedness Not Prepared 
N (%) 
Slightly/ Somewhat 
Prepared 
N (%) 
Moderately/ Highly 
Prepared 
N (%) 
Counseling patients about OTC-CBD products 72 (40.2) 70 (39.1) 37 (20.7) 
Discussing OTC-CBD with a health care 
provider 
69 (38.5) 72 (40.2) 38 (21.3) 
 
 
 
Table 5: Current cannabidiol education sought by survey participants 
 N (%) 
Continuing education obtained for cannabidiol in past 2 years 75 (42.0) 
Current primary resource for information for cannabidiol^  
 Illinois Board of Pharmacy 23 (13.0) 
 Illinois Department of Health 12 (6.8) 
 Illinois Pharmacist Association 33 (18.6) 
 Internet Searches 59 (33.3) 
 U. S. Food and Drug Administration 19 (10.7) 
 None. I have no interest in the topic 4 (2.3) 
 Other 27 (15.3) 
^ Participants were able to select more than one response on this question.  
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Figure 1: Knowledge about prescription CBD products that are FDA approved 
 
 
 
 
 
 
 
 
Figure 2: Which of the following are ways in which OTC-CBD is used? 
 
 
 
 
 
 
 
45.5%
11.9%
8.0%
4.5%
30.1%
Under the Federal Controlled Substances Act, cannabis derived cannabidiol 
(CBD) prescription drugs that contain no more than 0.3% 
tetrahydrocannabinols (THC) are classified under what drug schedule?
Correct response: Schedule V (30%)
Schedule I Schedule II Schedule III Schedule IV Schedule V
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Figure 3: Interest in future CBD education and its method of delivery 
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